TipRanks
Advertisement
Advertisement

DE:ANU Stock Latest News

XORTX Plans Q4 2026 FDA IND Filing for XRx-026 Gout Therapy
Company AnnouncementsXORTX Plans Q4 2026 FDA IND Filing for XRx-026 Gout Therapy
6d ago
6K
XRTX
Xortx Therapeutics announces planned FDA IND submission for XRx-026
PremiumThe Fly
Xortx Therapeutics announces planned FDA IND submission for XRx-026
6d ago
XRTX
XORTX Starts Clinical and Commercial Manufacturing of XORLO for Gout Program
PremiumCompany Announcements
XORTX Starts Clinical and Commercial Manufacturing of XORLO for Gout Program
13d ago
6K
XRTX
Xortx Therapeutics initiates clinical, commercial manufacturing of Xorlo
PremiumThe Fly
Xortx Therapeutics initiates clinical, commercial manufacturing of Xorlo
13d ago
XRTX
XORTX Re-Engages IR Firm After TSXV Delisting to Bolster Nasdaq-Focused Profile
PremiumCompany Announcements
XORTX Re-Engages IR Firm After TSXV Delisting to Bolster Nasdaq-Focused Profile
15d ago
XRTX
XORTX Therapeutics Finalizes TSXV Delisting and Re-engages IR Agency in US$2.5 Million Nasdaq-Focused Campaign
PremiumCompany AnnouncementsXORTX Therapeutics Finalizes TSXV Delisting and Re-engages IR Agency in US$2.5 Million Nasdaq-Focused Campaign
20d ago
6K
XRTX
XORTX Terminates IR Agreement, Postpones Marketing Amid TSXV Delisting
Premium
Company Announcements
XORTX Terminates IR Agreement, Postpones Marketing Amid TSXV Delisting
27d ago
6K
XRTX
Xortx Therapeutics terminates investor relations, marketing agreement
Premium
The Fly
Xortx Therapeutics terminates investor relations, marketing agreement
27d ago
XRTX
XORTX Therapeutics Files August Form 6-K Highlighting Stronger June 2026 Balance Sheet
PremiumCompany Announcements
XORTX Therapeutics Files August Form 6-K Highlighting Stronger June 2026 Balance Sheet
1M ago
6K
XRTX
XORTX Therapeutics Announces Resignation of Board Chairman Anthony Giovinazzo
PremiumCompany Announcements
XORTX Therapeutics Announces Resignation of Board Chairman Anthony Giovinazzo
2M ago
6K
XRTX
XORTX Therapeutics Adds Independent Director to Strengthen Board Oversight
PremiumCompany Announcements
XORTX Therapeutics Adds Independent Director to Strengthen Board Oversight
2M ago
6K
XRTX
Xortx Therapeutics announces Mika Grasso as co-CEO
PremiumThe Fly
Xortx Therapeutics announces Mika Grasso as co-CEO
3M ago
XRTX
PremiumCompany AnnouncementsXORTX Resets Strategy, Accelerates Gout Program and Names Mika Grasso Co-CEO
3M ago
6K
XRTX
Premium
Company Announcements
XORTX to Voluntarily Delist from TSX Venture Exchange, Maintain Nasdaq Listing
3M ago
6K
XRTX
Premium
Company Announcements
XORTX Raises US$5 Million in Public Offering to Fund Kidney and Gout Drug Programs
4M ago
6K
XRTX
PremiumCompany Announcements
XORTX files Q1 2026 unaudited results showing lower cash and equity
4M ago
6K
XRTX
Xortx Therapeutics 2.66M share Spot Secondary priced at $1.88
PremiumThe Fly
Xortx Therapeutics 2.66M share Spot Secondary priced at $1.88
4M ago
XRTX
PremiumCompany Announcements
XORTX Therapeutics Prices US$5 Million Public Offering to Fund Late-Stage Kidney and Gout Pipeline
4M ago
6K
XRTX
PremiumCompany Announcements
XORTX Says Preliminary Equity Levels Meet Nasdaq Listing Threshold
5M ago
6K
XRTX
PremiumCompany AnnouncementsXORTX Regains Nasdaq Listing Compliance After Reverse Stock Split
5M ago
6K
XRTX
Xortx Therapeutics meets Nasdaq continued listing requirements
Premium
The Fly
Xortx Therapeutics meets Nasdaq continued listing requirements
5M ago
XRTX
Premium
Company Announcements
XORTX Closes US$3 Million Acquisition of Vectus Kidney Anti‑Fibrotic Program
5M ago
6K
XRTX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >